Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03850535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Terminated
Start date
March 25, 2019
Completion date
September 10, 2020
Enrollment
24 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia